india glp-1 pharma companies develop versions of Wegovy to get in on weight-loss windfall India's weight-loss drug rush kicks

The authors of the study concluded that the GLP-1 receptor agonist lixisenatide had a three-point beneficial effect, when compared with placebo, in the change over a 12-month period from a baseline value of approximately 15 points on a 132-point scale measuring motor disability. The active arm improved 0.04 points in the lixisenatide group and worsened 3.04 points in the placebo group

Research-use GHK-Cu does not

Free Sample Available: Free samples are provided with a delivery time of 3-7 working days

Ros campaign is just one example of how marketers are adapting to the likes of Ozempic, Wegovy and Zepbound, drugs that are set to not only radically reduce BMIs but also treat a range of co-morbidities in their wake